DK0060027142
© Globe Newswire
22.12.2025
ALK B
LISTED
CPH
ALK – Financial calendar for the 2026 financial year
News Preview
2026 financial calendar for ALK (ALKB:DC / OMX: ALK B):...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2025
ALK B
LISTED
CPH
Major shareholder announcement
News Preview
Pursuant to Section 30 of the Danish Capital Markets Act, ALK (ALKB:DC / OMX: ALK B) hereby announces that Arbejdsmarkedets Tillægspension (“ATP”) (The Danish Supplementary Labour Market Pension) has informed ALK that ATP has reduced its ownership in ALK to below 5% of the share capital (previously 5.0%). The notification (in Danish) from ATP is at...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.12.2025
ALK B
LISTED
CPH
ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America
News Preview
ALK (ALKB:DC / OMX: ALK B) today announced the appointment of Edward Jordan as new Executive Vice President (EVP) and head of Commercial Operations in North America as per 5 January 2026. Edward Jordan succeeds Søren Niegel who has temporarily assumed the position following the decision, effective 1 October 2025, to elevate ALK’s two key commercial...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
12.11.2025
ALK B
LISTED
CPH
Nine-month interim report (Q3) 2025 (unaudited)
News Preview
ALK delivers 18% global organic revenue growth with operating profit up 41% in Q3...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
12.11.2025
ALK B
LISTED
CPH
ALK upgrades its full-year outlook
News Preview
Inside information...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ALK B
LISTED
CPH
Invitation to the presentation of ALK’s first nine months (Q3) 2025 results on Thursday, 13 November 2025
News Preview
ALK (ALKB.DC / OMX: ALK B) will publish its results for the first nine months (Q3) of 2025 in the morning on Thursday, 13 November 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ALK B
LISTED
CPH
ALK and GenSci partner to expand the AIT market in China
News Preview
Inside Information...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
ALK B
LISTED
CPH
ALK expands the Executive Leadership Team to include key commercial regions
News Preview
ALK (ALKB:DC / OMX: ALK B) today announced the decision to elevate its key commercial regions into the Executive Leadership Team (ELT) to further strengthen the execution of ALK’s strategy, Allergy+....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.08.2025
ALK B
LISTED
CPH
Six-month interim report (Q2) 2025 (unaudited)
News Preview
ALK delivers 12% organic revenue growth with operating profit up 41% in Q2...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.07.2025
ALK B
LISTED
CPH
ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system
News Preview
ALK (ALKB:DC / OMX: ALK B) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of the company’s tree pollen tablet ITULAZAX® for the treatment in adults. The recommendation allows for patients to gain access to ITULAZAX® through the National Health Service (NHS) systems in England, Wales, and No...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.07.2025
ALK B
LISTED
CPH
EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK
News Preview
Inside Information...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2025
ALK B
LISTED
CPH
First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany
News Preview
ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy® 2 mg (the trade name for neffy® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely emergency treatment of anaphylaxis represents a significant milestone for adults and children (≥30 kg) experiencing potentially life-threatening allerg...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
17.06.2025
ALK B
LISTED
CPH
ALK’s tablet mod træpollenallergi godkendt til allergivaccination af børn fra fem år
News Preview
Lægemiddelstyrelsen har netop godkendt Itulazax, den første tabletbaserede allergivaccination til behandling af børn og unge i alderen fem til 17 år med træpollenallergi i Danmark....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.06.2025
ALK B
LISTED
CPH
ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025
News Preview
At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took place in Glasgow, Scotland, from 13 to 16 June 2025, the Danish pharmaceutical company ALK presented extensive data on anaphylaxis and paediatric allergy....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
ALK B
LISTED
CPH
ALK participates at Jefferies Global Healthcare Conference 2025 in New York
News Preview
ALK (ALKB:DC / OMX: ALK B) today announced that the company is participating at the Jefferies Global Healthcare Conference 2025 in New York City taking place from 3 - 5 June 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.05.2025
ALK B
LISTED
CPH
ITULATEK® approved for treatment of children and adolescents in Canada
News Preview
ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s regulatory filing for ITULATEK® (tree pollen sublingual allergy immunotherapy tablet) for treatment of children and adolescents aged five to 17. Accordingly, the tree pollen tablet is now indicated for treatment of moderate to severe seasonal allergic rhinitis, with or...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.05.2025
ALK B
LISTED
CPH
Three-month interim report (Q1) 2025 (unaudited)
News Preview
ALK delivers 12% organic revenue growth with operating profit up 50% in Q1...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.04.2025
ALK B
LISTED
CPH
Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025
News Preview
ALK (ALKB.DC / OMX: ALK B) will publish its results for the first quarter of 2025 in the morning on Tuesday, 6 May 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.04.2025
ALK B
LISTED
CPH
Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
News Preview
ALK (ALKB:DC / OMX: ALK B / AKBLF): According to the company’s remuneration policy adopted at the company's Annual General Meeting on 14 March 2024 and in line with the company’s usual practice, the Board of Directors has passed a resolution to grant up to a total of 250,000 share-based instruments for the purpose of the company’s long-term incenti...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.03.2025
ALK B
LISTED
CPH
Annual General Meeting in ALK-Abelló A/S held on 13 March 2025
News Preview
ALK (ALKB:DC / OMX: ALK B / AKBLF): ALK-Abelló A/S held its Annual General Meeting on 13 March 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.03.2025
ALK B
LISTED
CPH
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
News Preview
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff:...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.02.2025
ALK B
LISTED
CPH
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
News Preview
ALK (ALKB:DC / OMX: ALK B / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff as set forth in the attached announcement....
Themefolio
Profiler
Peergroup
© Globe Newswire
19.02.2025
ALK B
LISTED
CPH
Annual report 2024: ALK delivers 15% sales growth with profits up 65%
News Preview
ALK’s (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the 2024 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook and represent the best results in the history of the company. ALK expects to continue its growth trajectory and earnings improvement in 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.02.2025
ALK B
LISTED
CPH
Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025
News Preview
ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its annual report for 2024 in the morning on Wednesday, 19 February 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.01.2025
ALK B
LISTED
CPH
ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system
News Preview
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of ACARIZAX® for the treatment of persistent, moderate to severe house dust mite allergic rhinitis in adults and adolescents. The recommendation paves the way for patients to gain access to ACARIZAX® through t...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.12.2024
ALK B
LISTED
CPH
ALK – Financial calendar for the 2025 financial year
News Preview
2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF):...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2024
ALK B
LISTED
CPH
ACARIZAX® approved in Europe for treatment of young children
News Preview
ALK (ALKB:DC / OMX: ALK B) today announced that its European regulatory filing for ACARIZAX® (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been approved by the health authorities in 21 EU countries via a type II variation procedure. The first market introductions, including in ALK’s largest market,...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.11.2024
ALK B
LISTED
CPH
Nine-month interim report (Q3) 2024 (unaudited)
News Preview
Company release No. 19/2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.11.2024
ALK B
LISTED
CPH
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
News Preview
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY). The agreement grants ALK exclusive global rights to the neffy® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal deli...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2024
ALK B
LISTED
CPH
Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024
News Preview
ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first nine months (Q3) 2024 in the morning of Thursday 14 November 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.08.2024
ALK B
LISTED
CPH
Six-month interim report (Q2) 2024
News Preview
Company release No. 16/2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.08.2024
ALK B
LISTED
CPH
ALK upgrades its full-year revenue and earnings outlook
News Preview
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect the current performance and outlook for the remainder of the year....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.08.2024
ALK B
LISTED
CPH
Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024
News Preview
ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first six months (Q2) 2024 in the morning of 23 August 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.06.2024
ALK B
LISTED
CPH
ALK upgrades its full-year revenue and earnings outlook
News Preview
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect better than expected sales performance in Q2 and an improved outlook for the remainder of the year....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.06.2024
ALK B
LISTED
CPH
ALK provides update on regulatory process for the house dust mite allergy tablet in China
News Preview
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that it has decided to withdraw the Biologic License Application (‘BLA’) for its house dust mite (‘HDM’) sublingual allergy immunotherapy tablet in China. ALK will continue to work with the authorities to obtain regulatory approval of the HDM tablet in China, which may involve establishing addition...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2024
ALK B
LISTED
CPH
ALK launches new growth strategy and 2028 financial ambitions
News Preview
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the Board of Directors has adopted a new corporate strategy (Allergy+) and 2028 financial ambitions....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2024
ALK B
LISTED
CPH
ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies
News Preview
At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took part in Valencia in Spain from 31 May to 3 June 2024, the Danish pharmaceutical company ALK presented new data from two paediatric phase 3 clinical trials evaluating SQ sublingual immunotherapy (SLIT) tablets in house dust mite (HDM) and tree pollen...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.05.2024
ALK B
LISTED
CPH
Listen in on ALK’s Capital Markets Day on 4 June 2024
News Preview
ALK (ALKB:DC / OMX: ALK B / AKBLF) will host a Capital Markets Day on 4 June at 13.00-17.00....
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2024
ALK B
LISTED
CPH
Three-month interim report (Q1) 2024 (unaudited)
News Preview
Company release No. 11/2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2024
ALK B
LISTED
CPH
ALK upgrades its full-year revenue outlook
News Preview
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the 2024 full-year financial outlook has been updated....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
